Hypertension and CKD form a self-amplifying cycle — each worsens the other through mechanisms you need to understand at the pharmacological level. This module asks you to go beyond which drug to use and instead explain why: why RAAS inhibitors are renoprotective through mechanisms independent of blood pressure lowering; why a creatinine rise after starting an ACEi does not mean the drug is causing harm; why the diuretic class must change as eGFR declines; and why SGLT2 inhibitors reduce intraglomerular pressure through a fundamentally different mechanism than RAAS inhibitors. These are the conceptual building blocks of hypertension management in CKD. If you can explain the pharmacological reasoning behind each question, you are thinking at the level this module demands.
1. Which of the following most accurately describes the bidirectional relationship between hypertension and chronic kidney disease, and the central pharmacological implication of this relationship?
A) Hypertension causes CKD through glomerulosclerosis, but CKD does not worsen hypertension — the kidneys are passive victims of elevated blood pressure and do not contribute to its perpetuation
B) CKD causes hypertension exclusively through RAAS activation — sodium retention and sympathetic stimulation do not contribute; RAAS inhibition is therefore the only pharmacological intervention needed
C) Hypertension and CKD are associated but not causally related — the apparent bidirectionality reflects shared risk factors such as age, diabetes, and obesity rather than true physiological interaction
D) Hypertension causes CKD through hypertensive nephrosclerosis, but once CKD is established it becomes independent of blood pressure — antihypertensive therapy loses efficacy in established CKD
E) Hypertension and CKD exist in a self-amplifying bidirectional cycle — hypertension causes CKD through hypertensive nephrosclerosis and intraglomerular hypertension; CKD perpetuates and worsens hypertension through sodium retention (reduced nephron mass and impaired pressure-natriuresis), RAAS activation (ischemic juxtaglomerular cells releasing renin), and sympathetic stimulation (afferent renal nerve activation from damaged kidney tissue); the pharmacological implication is that interventions must simultaneously lower systemic blood pressure and protect the glomerulus from the intraglomerular hypertension that drives progressive nephron loss independently of systemic BP
ANSWER: E
Rationale:
The bidirectional relationship between hypertension and CKD is one of the foundational concepts in nephrology pharmacology. Hypertension causes CKD through two primary mechanisms: hypertensive nephrosclerosis (ischemic injury to afferent arterioles and glomeruli from chronic pressure overload) and intraglomerular hypertension (elevated pressure within the glomerular capillaries that drives proteinuria and progressive glomerulosclerosis). Once CKD is established, the damaged kidney perpetuates hypertension through multiple independent mechanisms: reduced functioning nephron mass impairs sodium excretion, resetting the pressure-natriuresis curve to a higher operating point; ischemic nephrons activate juxtaglomerular cells to release renin, sustaining angiotensin II-mediated vasoconstriction and aldosterone-driven sodium retention even in the face of volume expansion; and damaged kidney tissue activates afferent renal sympathetic nerves, increasing systemic sympathetic outflow and renin release. The pharmacological implication is that simply lowering blood pressure is insufficient — interventions must also specifically target intraglomerular pressure (through RAAS inhibition's efferent arteriolar dilation), proteinuria (both as a marker and independent driver of progression), and the multiple mechanisms by which CKD sustains hypertension.
Option A: Option A is incorrect because CKD actively perpetuates hypertension through multiple mechanisms.
Option B: Option B is incorrect because sodium retention and sympathetic activation are also major drivers of CKD-related hypertension.
Option C: Option C is incorrect because the causal relationship between hypertension and CKD is well-established with specific mechanistic pathways in both directions.
Option D: Option D is incorrect because antihypertensive therapy — particularly RAAS inhibition — retains and in fact provides its greatest absolute benefit in established CKD.
2. Which of the following most accurately explains why RAAS inhibitors reduce proteinuria and slow CKD progression through mechanisms that are independent of and additive to their systemic blood pressure-lowering effect?
A) RAAS inhibitors reduce proteinuria by directly blocking albumin transport receptors in the glomerular filtration barrier — this receptor-mediated mechanism operates independently of hemodynamic effects and is responsible for most of the renoprotection observed in clinical trials
B) RAAS inhibitors dilate the efferent glomerular arteriole by blocking angiotensin II-mediated efferent arteriolar constriction — this specifically reduces intraglomerular hydrostatic pressure, directly decreasing the pressure-driven filtration of protein across the glomerular basement membrane; additionally, RAAS inhibitors reduce TGF-beta-mediated fibrosis, decrease glomerular basement membrane permeability to protein, and attenuate aldosterone-driven interstitial inflammation; these mechanisms operate independently of systemic blood pressure, explaining why RAAS inhibitors provide greater renoprotection than other antihypertensives achieving equivalent systemic BP reduction
C) RAAS inhibitors reduce proteinuria entirely through systemic blood pressure lowering — the IDNT trial showed irbesartan and amlodipine were equivalent for proteinuria reduction when systemic BP was equally controlled, confirming that BP reduction is the sole mechanism
D) RAAS inhibitors reduce intraglomerular pressure by constricting the afferent arteriole through angiotensin II blockade — reduced afferent tone decreases glomerular blood flow, lowering filtration pressure and proteinuria
E) RAAS inhibitors reduce proteinuria exclusively through their diuretic effect — sodium depletion reduces plasma volume, lowering glomerular filtration pressure and protein filtration; this mechanism explains the enhanced renoprotection when RAAS inhibitors are combined with diuretics
ANSWER: B
Rationale:
The renoprotective mechanism of RAAS inhibitors is primarily hemodynamic at the glomerular level, operating through a mechanism distinct from systemic blood pressure lowering. Angiotensin II preferentially constricts the efferent glomerular arteriole relative to the afferent arteriole — this is its primary site of action within the glomerular microcirculation. This efferent constriction maintains intraglomerular hydrostatic pressure, which is necessary for ultrafiltration but also drives protein filtration across the glomerular basement membrane when intraglomerular pressure is elevated. RAAS inhibitors (ACEi and ARBs) block angiotensin II production or action, removing this efferent arteriolar constriction — dilating the efferent arteriole and reducing intraglomerular pressure. This directly reduces proteinuria and slows the pressure-driven glomerulosclerosis that is the final common pathway of most progressive CKD. The IDNT trial specifically confirmed this mechanism: irbesartan reduced the primary renal endpoint by 20% compared to placebo and by 23% compared to amlodipine despite equivalent systemic BP control between the ARB and amlodipine arms — proving that the renoprotective benefit is not solely explained by systemic BP lowering. Additional mechanisms contributing to RAAS inhibitor renoprotection include reduction of TGF-beta-mediated glomerular and interstitial fibrosis, reduction of glomerular filtration barrier permeability to protein (beyond the pressure effect), and attenuation of aldosterone-driven interstitial inflammation.
Option A: Option A is incorrect because RAAS inhibitors do not block albumin transport receptors.
Option C: Option C is incorrect because IDNT demonstrated irbesartan was superior to amlodipine at equivalent BP — proving mechanisms beyond BP lowering.
Option D: Option D is incorrect because RAAS inhibitors dilate the efferent arteriole — not constrict the afferent; afferent constriction is the mechanism of tubuloglomerular feedback, not RAAS inhibition.
Option E: Option E is incorrect because the primary mechanism is hemodynamic (efferent dilation), not diuretic volume depletion.
3. A patient with CKD stage 3a (eGFR 54 mL/min/1.73m2) and UACR 380 mg/g is started on ramipril 5 mg daily. At the 4-week check, creatinine has risen from 1.2 to 1.55 mg/dL (a 29% increase) and potassium from 4.1 to 4.9 mEq/L. BP is 126/78 mmHg and UACR has fallen to 230 mg/g. Which of the following most accurately identifies whether these laboratory changes indicate the drug should be continued, dose-reduced, or discontinued?
A) Discontinue ramipril immediately — a creatinine rise of any magnitude following RAAS inhibitor initiation in CKD indicates nephrotoxicity and permanent discontinuation is required; the UACR reduction is coincidental
B) Reduce ramipril to 2.5 mg immediately — the creatinine rise of 29% approaches the acceptable limit; dose reduction is mandatory before the rise exceeds 30%; potassium of 4.9 mEq/L is dangerously elevated and requires immediate drug reduction
C) Continue ramipril but add a potassium binder immediately — potassium of 4.9 mEq/L combined with a creatinine rise requires potassium binder initiation before the next clinic visit regardless of dietary factors
D) Continue ramipril at the current dose — the 29% creatinine rise is within the accepted threshold of up to 30–35% and reflects the expected and intended reduction in intraglomerular pressure; the 40% UACR reduction from 380 to 230 mg/g confirms a favorable antiproteinuric response; potassium of 4.9 mEq/L warrants dietary potassium counseling and recheck in 2–4 weeks but does not require drug modification at this level; these findings together indicate that ramipril is working as intended
E) Continue ramipril and add spironolactone for additional antiproteinuric benefit — the residual UACR of 230 mg/g indicates incomplete RAAS inhibition; dual MRA plus ACEi therapy will further reduce proteinuria
ANSWER: D
Rationale:
This presentation is the archetypal scenario for correct RAAS inhibitor interpretation in CKD. The 29% creatinine rise is within the accepted threshold of 30–35% that reflects the intended pharmacological effect of RAAS inhibition — reduction of intraglomerular pressure through efferent arteriolar dilation reduces the GFR driving force, producing a predictable creatinine elevation that indicates the drug is working. This is not nephrotoxicity; it is the mechanism of renoprotection. Long-term follow-up studies consistently show that patients who experience this hemodynamic creatinine rise with RAAS inhibitors have better renal outcomes than those who do not, because the intraglomerular pressure reduction is the very mechanism that slows glomerulosclerosis. The 40% UACR reduction (380 to 230 mg/g) further confirms a robust antiproteinuric response. Potassium of 4.9 mEq/L is above normal but below the action threshold — dietary potassium counseling (reduce high-potassium foods: bananas, potatoes, oranges, tomatoes) and recheck in 2–4 weeks is the appropriate response. Drug modification is not required until potassium consistently exceeds 5.5 mEq/L.
Option A: Option A is incorrect because a creatinine rise of up to 30–35% is expected and beneficial, not an indication for discontinuation.
Option B: Option B is incorrect because 29% is within the acceptable range and potassium of 4.9 mEq/L does not require dose reduction — the threshold for action is 5.0–5.5 mEq/L.
Option C: Option C is incorrect because potassium of 4.9 mEq/L does not require immediate potassium binder initiation; dietary counseling and monitoring are appropriate.
Option E: Option E is incorrect because adding spironolactone to an ACEi in CKD with concurrent RAAS inhibition carries significant hyperkalemia risk and is not the appropriate next step; finerenone is the preferred MRA if additional proteinuria reduction is needed in this setting.
4. Which of the following most accurately describes the landmark evidence from the RENAAL and IDNT trials that established ARBs as renoprotective therapy in type 2 diabetic nephropathy?
A) RENAAL (losartan versus placebo in type 2 diabetic nephropathy) demonstrated a 16% reduction in the primary composite endpoint of doubling of serum creatinine, ESRD, or death, and a 28% reduction in ESRD alone; IDNT (irbesartan versus amlodipine versus placebo in type 2 diabetic nephropathy) demonstrated irbesartan reduced the primary composite endpoint by 20% versus placebo and 23% versus amlodipine despite equivalent systemic blood pressure control between the irbesartan and amlodipine arms — the superiority of irbesartan over amlodipine at equivalent BP is the definitive evidence that ARB renoprotection operates through mechanisms beyond blood pressure lowering
B) RENAAL demonstrated that losartan was superior to amlodipine for renal outcomes at equivalent BP, confirming RAAS-specific renoprotection beyond BP lowering; IDNT demonstrated that irbesartan was superior to placebo but equivalent to ramipril for renal outcomes, establishing ARBs as non-inferior to ACEi in type 2 diabetic nephropathy
C) RENAAL demonstrated that losartan reduced the risk of ESRD by 50% in type 1 diabetic nephropathy; IDNT demonstrated irbesartan reduced the risk of ESRD by 50% in type 2 diabetic nephropathy; together these trials established RAAS inhibition as the cornerstone of renoprotection across both types of diabetic nephropathy
D) RENAAL demonstrated that losartan plus amlodipine was superior to losartan alone for renal outcomes in type 2 diabetic nephropathy, establishing the combination as the preferred initial regimen; IDNT confirmed this finding with irbesartan
E) RENAAL and IDNT both used placebo controls only and did not include active comparator arms — the superiority of ARBs over placebo in these trials cannot distinguish between BP-mediated and RAAS-specific renoprotection, making these trials insufficient to establish ARB-specific renoprotection
ANSWER: A
Rationale:
RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) enrolled 1,513 patients with type 2 diabetes, nephropathy (creatinine 1.3–3.0 mg/dL, proteinuria ≥0.5 g/day), and randomized them to losartan versus placebo on background antihypertensive therapy. Losartan reduced the primary composite endpoint (doubling of serum creatinine, ESRD, or death) by 16% and ESRD alone by 28% compared to placebo. IDNT (Irbesartan Diabetic Nephropathy Trial) enrolled patients with type 2 diabetic nephropathy and randomized them to irbesartan, amlodipine, or placebo. The critical design feature of IDNT was its active amlodipine comparator — allowing the renoprotective effect of irbesartan to be separated from its antihypertensive effect. Irbesartan reduced the primary composite endpoint by 20% versus placebo and by 23% versus amlodipine despite virtually identical achieved systolic BP between the irbesartan and amlodipine arms. This direct head-to-head comparison is the definitive evidence that ARB renoprotection is not purely blood pressure-mediated — the same BP reduction through a CCB (no effect on intraglomerular pressure) produced worse renal outcomes than through an ARB (reducing intraglomerular pressure).
Option B: Option B is incorrect because RENAAL compared losartan to placebo, not to amlodipine; and IDNT did not include ramipril as a comparator.
Option C: Option C is incorrect because RENAAL and IDNT studied type 2 diabetic nephropathy; the 50% reduction figures apply to the Lewis et al. captopril trial in type 1 diabetic nephropathy.
Option D: Option D is incorrect because neither RENAAL nor IDNT tested combination ARB plus CCB versus ARB alone as their primary comparison.
Option E: Option E is incorrect because IDNT specifically included an amlodipine active comparator, making it possible to distinguish BP-mediated from RAAS-specific renoprotection.
5. Which of the following most accurately identifies the blood pressure target recommended by KDIGO 2021 for most patients with CKD, and the important measurement caveat that affects interpretation of this target?
A) KDIGO 2021 recommends a target systolic BP of below 140 mmHg for all CKD patients — this is the same target as for the general hypertensive population; no measurement caveat applies as KDIGO uses standard attended office blood pressure measurement
B) KDIGO 2021 recommends a target systolic BP of below 150 mmHg for CKD patients over age 65, and below 130 mmHg for younger patients — the measurement caveat is that all readings must be taken after 10 minutes of supine rest
C) KDIGO 2021 recommends a target systolic BP of below 120 mmHg for most adult patients with CKD when tolerated, based on standardized blood pressure measurement; the critical measurement caveat is that KDIGO adopted the SPRINT measurement methodology — automated unattended office blood pressure (AOBP) — which yields readings approximately 5–10 mmHg lower than standard attended office measurement; the KDIGO target of below 120 mmHg by AOBP therefore approximates below 130–135 mmHg by standard attended measurement, aligning with the ACC/AHA 2017 target of below 130/80 mmHg
D) KDIGO 2021 recommends a target systolic BP of below 130 mmHg for CKD with diabetes and below 140 mmHg for CKD without diabetes — the measurement caveat is that home blood pressure monitoring must be used rather than office measurement in all CKD patients
E) KDIGO 2021 does not specify a numeric blood pressure target for CKD — it recommends individualized targets based on age, proteinuria severity, and cardiovascular risk without a universal threshold
ANSWER: C
Rationale:
The KDIGO 2021 Blood Pressure in CKD guideline represented a significant evolution in BP target recommendations for CKD. Drawing primarily on SPRINT data (which enrolled a large CKD subgroup) and other intensive control trial evidence, KDIGO 2021 recommended targeting systolic BP below 120 mmHg for most adult patients with CKD when this can be tolerated. The critical measurement caveat — frequently misunderstood in clinical practice — is that KDIGO adopted standardized BP measurement methodology consistent with SPRINT: automated unattended office blood pressure (AOBP), in which patients sit alone in a quiet room and the device automatically takes multiple readings without observer presence. AOBP yields readings approximately 5–10 mmHg lower than conventional attended office measurement (where the presence of a clinician produces a modest white-coat effect). Therefore, the KDIGO target of below 120 mmHg using AOBP is approximately equivalent to 130–135 mmHg by standard attended measurement — explaining why the ACC/AHA 2017 guideline (which uses standard measurement) sets its target at below 130/80 mmHg, and why these two guidelines are not as discordant as the numbers suggest.
Option A: Option A is incorrect because KDIGO 2021 recommended a more intensive target than 140 mmHg.
Option B: Option B is incorrect because KDIGO 2021 did not stratify the target by age in this manner, and the supine rest measurement is not the KDIGO methodology.
Option D: Option D is incorrect because KDIGO 2021 set a unified target rather than separate diabetes/non-diabetes targets; and home BP monitoring was not specified as the required measurement method.
Option E: Option E is incorrect because KDIGO 2021 did specify a numeric systolic BP target of below 120 mmHg.
6. Which of the following most accurately describes why the diuretic class must change as CKD progresses from stage 3 to stage 4, and which diuretic is preferred at each stage?
A) Thiazide diuretics remain the preferred diuretic at all CKD stages — chlorthalidone retains full antihypertensive efficacy even at eGFR below 15 mL/min/1.73m2 because its mechanism of action (NCC inhibition) does not depend on tubular secretion; loop diuretics are only needed for acute volume overload requiring rapid diuresis
B) Loop diuretics become preferred in CKD stage 3 (eGFR below 60 mL/min/1.73m2) — thiazide diuretics lose all efficacy immediately upon entering stage 3 because NCC transporter expression is reduced to zero in CKD; furosemide is the preferred loop diuretic at all stages below eGFR 60 mL/min/1.73m2
C) Potassium-sparing diuretics (spironolactone, eplerenone) become the preferred class in CKD stage 3 and 4 — their mechanism of action at the collecting duct is independent of GFR, providing sustained natriuresis without the electrolyte disturbances of thiazides or the ototoxicity of loop diuretics
D) MRAs (spironolactone or eplerenone) are added to thiazide-type diuretics at CKD stage 3 as the preferred intensification strategy — the PATHWAY-2 evidence applies to CKD patients and spironolactone remains the most effective fourth-line diuretic regardless of eGFR
E) Thiazide-type diuretics (chlorthalidone, indapamide) retain meaningful antihypertensive efficacy through most of CKD stage 3 (eGFR 30–59 mL/min/1.73m2) but become substantially less effective as eGFR falls toward stage 4 (below 30 mL/min/1.73m2), because thiazides must be actively secreted into the proximal tubule via organic anion transporters to reach their site of action at the NCC transporter; at eGFR below approximately 30 mL/min/1.73m2, both reduced tubular secretory capacity and competition from accumulated uremic organic acids impair this delivery; loop diuretics (torsemide preferred over furosemide for its more predictable approximately 80% oral bioavailability) become the diuretic of choice at stage 4
ANSWER: E
Rationale:
Understanding the pharmacokinetic basis for the thiazide-to-loop diuretic transition is essential for managing hypertension in progressive CKD. Thiazide and thiazide-like diuretics (chlorthalidone, indapamide, HCTZ) are organic acids that must be actively secreted into the proximal tubular lumen via organic anion transporters (OAT1 and OAT3) to reach their site of action at the NCC transporter in the distal convoluted tubule. As GFR declines, two mechanisms reduce thiazide delivery to the tubular lumen: first, reduced tubular secretory capacity means less drug reaches the NCC; second, accumulated uremic organic acids compete for the same proximal tubule transporters, further reducing thiazide secretion. The CLICK trial (2021) demonstrated that chlorthalidone 12.5–25 mg retained meaningful antihypertensive activity (reducing 24-hour ambulatory systolic BP by 11 mmHg versus placebo) in CKD stage 3–4 patients on background RAAS inhibition — confirming that some thiazide activity persists into stage 4. However, at eGFR below approximately 30 mL/min/1.73m2, thiazide efficacy is substantially reduced and loop diuretics become the diuretic of choice. Loop diuretics act at the NKCC2 transporter in the thick ascending limb, which has a much higher natriuretic ceiling. Torsemide is preferred over furosemide for its predictable approximately 80% oral bioavailability (compared to furosemide's highly variable 10–100% intestinal absorption).
Option A: Option A is incorrect because thiazides do require tubular secretion and lose efficacy at low eGFR.
Option B: Option B is incorrect because the transition to loop diuretics is gradual through stage 3, not immediate at eGFR 60 mL/min/1.73m2.
Option C: Option C is incorrect because MRAs (spironolactone, eplerenone) carry high hyperkalemia risk in stage 3–4 CKD with concurrent RAAS inhibition and are not the preferred diuretic class at these stages.
Option D: Option D is incorrect because PATHWAY-2 enrolled patients without advanced CKD; the spironolactone recommendation does not override the hyperkalemia concerns at advanced CKD stages.
7. Which of the following most accurately describes the mechanism by which SGLT2 inhibitors reduce intraglomerular pressure through tubuloglomerular feedback (TGF) restoration, and why this mechanism is complementary to rather than redundant with RAAS inhibitor renoprotection?
A) SGLT2 inhibitors reduce intraglomerular pressure by blocking AT1 receptors on afferent arteriolar smooth muscle cells — this is complementary to ARB therapy which blocks AT1 receptors on efferent arteriolar cells; the two drug classes together provide complete AT1 receptor blockade across the entire glomerular microcirculation
B) SGLT2 inhibitors block glucose and sodium co-reabsorption in the proximal tubule via the SGLT2 transporter — this increases distal sodium delivery to the macula densa, restoring the tubuloglomerular feedback mechanism that was suppressed in diabetic and hyperfiltrating nephrons; restored TGF causes afferent arteriolar constriction that reduces glomerular blood flow and intraglomerular pressure; this is complementary to RAAS inhibition (which dilates the efferent arteriole) because the two mechanisms address opposite ends of the glomerular microcirculation — SGLT2 inhibitors reduce inflow through afferent constriction, RAAS inhibitors reduce outflow resistance through efferent dilation; together they produce greater intraglomerular pressure reduction than either alone
C) SGLT2 inhibitors reduce intraglomerular pressure exclusively through their systemic diuretic effect — osmotic diuresis reduces intravascular volume, lowering renal perfusion pressure and intraglomerular pressure; this is additive to RAAS inhibition's direct glomerular effects
D) SGLT2 inhibitors reduce intraglomerular pressure by stimulating efferent arteriolar constriction through adenosine release at the macula densa — adenosine binds A1 receptors on efferent arteriolar smooth muscle, increasing outflow resistance and thereby reducing intraglomerular pressure through a mechanism analogous to angiotensin II
E) SGLT2 inhibitors reduce intraglomerular pressure by directly inhibiting the NHE3 transporter in the proximal tubule — this is distinct from their SGLT2-mediated glucose transport inhibition and is responsible for the majority of the intraglomerular pressure reduction observed in clinical trials
ANSWER: B
Rationale:
The mechanism by which SGLT2 inhibitors reduce intraglomerular pressure requires understanding of tubuloglomerular feedback — one of the kidney's fundamental autoregulatory mechanisms. In healthy physiology, when distal sodium delivery to the macula densa increases, TGF causes afferent arteriolar constriction that reduces GFR — a protective mechanism preventing excessive filtration. In diabetic and non-diabetic CKD with hyperfiltration, SGLT2-mediated avid sodium reabsorption in the proximal tubule reduces distal sodium delivery to the macula densa, suppressing TGF and allowing pathological afferent arteriolar dilation and glomerular hyperfiltration. SGLT2 inhibitors block glucose and sodium co-reabsorption at the proximal tubule, increasing distal sodium delivery to the macula densa and restoring normal TGF — causing afferent arteriolar constriction and reducing intraglomerular pressure. The complementarity with RAAS inhibitors is anatomically precise: SGLT2 inhibitors reduce inflow pressure (afferent arteriolar constriction via TGF), while RAAS inhibitors reduce outflow resistance (efferent arteriolar dilation by removing angiotensin II-mediated constriction). Together they address both ends of the glomerular capillary bed, producing greater intraglomerular pressure reduction than either class alone. The adenosine mechanism in option D is partially correct as a molecular detail (adenosine is the macula densa signal mediating TGF-induced afferent constriction) but incorrectly attributes its effect to the efferent rather than afferent arteriole.
Option A: Option A is incorrect because SGLT2 inhibitors do not block AT1 receptors.
Option C: Option C is incorrect because the TGF restoration mechanism operates independently of the systemic diuretic effect and is not solely explained by volume depletion.
Option E: Option E is incorrect because NHE3 inhibition is a secondary mechanism of SGLT2 inhibitors; the primary renoprotective mechanism is TGF restoration through SGLT2 blockade.
8. Which of the following correctly identifies why dual RAAS blockade (ACEi plus ARB simultaneously) is contraindicated in CKD despite the theoretical appeal of more complete RAAS suppression, and what trial provided the definitive evidence?
A) Dual RAAS blockade is contraindicated in CKD because both ACEi and ARBs are renally eliminated — combining them doubles the plasma half-life through competitive elimination, causing toxic accumulation; the ONTARGET trial confirmed this pharmacokinetic interaction
B) Dual RAAS blockade is contraindicated because ACEi and ARBs compete for the same AT1 receptor binding site, producing pharmacological antagonism rather than additivity; the VA NEPHRON-D trial confirmed that the combination was less effective than either agent alone for proteinuria reduction
C) Dual RAAS blockade is contraindicated exclusively in patients with potassium above 4.5 mEq/L at baseline — patients with normal potassium can safely receive the combination; the VA NEPHRON-D trial only enrolled patients with pre-existing hyperkalemia
D) Dual RAAS blockade (ACEi plus ARB) is contraindicated in CKD because the combination produces excessive reduction of efferent arteriolar tone — both drugs remove angiotensin II-mediated efferent constriction simultaneously, causing glomerular perfusion pressure to fall below the level needed to maintain GFR when renal perfusion is compromised; the VA NEPHRON-D trial in type 2 diabetic nephropathy demonstrated that the combination of lisinopril plus losartan produced no additional benefit for the primary renal composite endpoint compared to either agent alone, while significantly increasing rates of AKI, hyperkalemia, and hypotension; dual RAAS blockade is therefore contraindicated in clinical practice
E) Dual RAAS blockade is contraindicated only in CKD stage 4 and 5 — in CKD stage 1 through 3, the combination of ACEi plus ARB provides superior proteinuria reduction and is guideline-recommended for patients with UACR above 300 mg/g; the VA NEPHRON-D trial only enrolled stage 4 and 5 patients
ANSWER: D
Rationale:
The theoretical appeal of dual RAAS blockade — combining an ACEi (blocking angiotensin II production) with an ARB (blocking AT1 receptor activation) to achieve more complete RAAS suppression — was tested in clinical trials after observational data suggested additive antiproteinuric effects in small studies. The VA NEPHRON-D (Veterans Affairs Nephropathy in Diabetes) trial enrolled 1,448 patients with type 2 diabetic nephropathy and randomized them to lisinopril plus losartan versus losartan alone. The trial was stopped early due to harm: the combination provided no significant reduction in the primary renal composite endpoint (decline in eGFR, ESRD, or death) compared to losartan alone, while producing significantly higher rates of AKI (requiring hospitalization or dialysis), hyperkalemia requiring dose reduction or hospitalization, and symptomatic hypotension. The mechanistic basis for the harm is excess reduction of efferent arteriolar tone: angiotensin II normally maintains intraglomerular pressure by constricting the efferent arteriole; when both ACE and AT1 receptors are simultaneously blocked, the loss of this efferent support is maximal. Under conditions of reduced renal perfusion (volume depletion, hypotension, intercurrent illness), this can precipitate acute ischemic kidney injury. ONTARGET also demonstrated harm from dual RAAS blockade in a broader cardiovascular risk population. KDIGO guidelines specifically advise against routine dual RAAS blockade in CKD.
Option A: Option A is incorrect because neither ACEi nor ARBs accumulate through competitive pharmacokinetic interaction — this mechanism does not exist.
Option B: Option B is incorrect because ACEi and ARBs act on different molecular targets (ACE enzyme versus AT1 receptor) and do not compete pharmacologically.
Option C: Option C is incorrect because the contraindication applies to all patients with CKD regardless of baseline potassium.
Option E: Option E is incorrect because dual RAAS blockade is contraindicated across all CKD stages per KDIGO guidelines; VA NEPHRON-D enrolled patients with eGFR up to 60 mL/min/1.73m2.
9. Which of the following correctly identifies the landmark renal outcome data from the CREDENCE and DAPA-CKD trials, and what feature of DAPA-CKD was particularly significant for broadening the indication of SGLT2 inhibitors?
A) CREDENCE demonstrated a 40% relative risk reduction in the primary composite renal endpoint with canagliflozin in type 2 diabetes and CKD (eGFR 30–90 mL/min/1.73m2, UACR ≥300 mg/g) on background RAAS inhibition, and a 30% reduction in ESRD; DAPA-CKD demonstrated a 39% reduction in the primary composite endpoint with dapagliflozin in patients with CKD (eGFR 25–75 mL/min/1.73m2, UACR ≥200 mg/g) both with and without type 2 diabetes — the inclusion of non-diabetic CKD patients in DAPA-CKD was the feature that significantly broadened the indication of SGLT2 inhibitors beyond diabetes management to primary renal protection in CKD regardless of etiology
B) CREDENCE demonstrated that canagliflozin reduced ESRD by 30% but had no effect on cardiovascular outcomes in diabetic CKD; DAPA-CKD demonstrated that dapagliflozin was effective only in patients with type 2 diabetes — the non-diabetic subgroup showed no significant benefit; both trials were therefore limited to diabetic nephropathy indications
C) CREDENCE enrolled patients with CKD stage 1 and 2 only (eGFR above 60 mL/min/1.73m2) and demonstrated preventive benefit of early SGLT2 inhibitor use; DAPA-CKD enrolled patients with more advanced CKD (eGFR 25–75 mL/min/1.73m2) and demonstrated treatment benefit in established proteinuric CKD
D) CREDENCE and DAPA-CKD both used cardiovascular death as their primary endpoint — the renal benefits in these trials were secondary endpoints that did not achieve statistical significance; the primary indication for SGLT2 inhibitors in CKD remains cardiovascular protection rather than renal protection
E) CREDENCE demonstrated benefit only in patients with eGFR above 60 mL/min/1.73m2 — patients with eGFR below 60 mL/min/1.73m2 showed no significant benefit; DAPA-CKD was terminated early due to excess adverse events in the dapagliflozin arm in patients with eGFR below 30 mL/min/1.73m2
ANSWER: A
Rationale:
CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) was a landmark trial enrolling 4,401 patients with type 2 diabetes and nephropathy (eGFR 30–90 mL/min/1.73m2, UACR ≥300 mg/g) on background maximum tolerated RAAS inhibition. It was stopped early due to overwhelming benefit: canagliflozin reduced the primary composite renal endpoint (doubling of serum creatinine, ESRD, or renal/cardiovascular death) by approximately 30% and ESRD alone by approximately 30%. DAPA-CKD (Study of the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease) enrolled 4,304 patients with CKD (eGFR 25–75 mL/min/1.73m2, UACR ≥200 mg/g) — critically including approximately one-third of patients without type 2 diabetes. The trial demonstrated a 39% relative risk reduction in the primary composite endpoint (sustained ≥50% eGFR decline, ESRD, or death from renal or cardiovascular causes). Crucially, the renal benefit was consistent across patients with and without diabetes — establishing for the first time that SGLT2 inhibitor renoprotection is not glucose-dependent but rather operates through the intraglomerular pressure-reducing mechanism (TGF restoration) that is relevant in any proteinuric CKD regardless of etiology. This broadened the indication from diabetic nephropathy to proteinuric CKD as a disease state.
Option B: Option B is incorrect because DAPA-CKD demonstrated benefit in non-diabetic CKD — the non-diabetic subgroup showed consistent benefit.
Option C: Option C is incorrect about CREDENCE's eGFR range — it included CKD stage 2 and 3 (eGFR 30–90 mL/min/1.73m2).
Option D: Option D is incorrect because both trials used composite renal endpoints as their primary outcome, which reached statistical significance.
Option E: Option E is incorrect because CREDENCE enrolled down to eGFR 30 mL/min/1.73m2, not exclusively above 60; and DAPA-CKD was stopped early due to clear benefit, not harm.
10. Which of the following most accurately describes the role of finerenone in CKD management, how it differs pharmacologically from spironolactone and eplerenone, and which patient population has the strongest evidence base for its use?
A) Finerenone is a loop diuretic with MRA properties — it combines natriuresis (through NKCC2 blockade) with aldosterone receptor antagonism; it is preferred over spironolactone in CKD because its diuretic effect offsets the hyperkalemia caused by MRA-mediated potassium retention; the evidence base supports its use in all CKD stages including stage 5
B) Finerenone is pharmacologically identical to eplerenone — both are selective non-steroidal MRAs; finerenone has no clinical advantages over eplerenone in CKD other than once-daily versus twice-daily dosing; the FIDELIO-DKD trial demonstrated equivalent outcomes for finerenone and eplerenone in type 2 diabetic CKD
C) Finerenone is a non-steroidal, highly selective mineralocorticoid receptor antagonist — unlike spironolactone (which causes gynecomastia and sexual dysfunction through off-target androgen and progesterone receptor binding) and eplerenone (which is a selective steroidal MRA with less potency per mg and shorter duration), finerenone has a distinct chemical scaffold that confers higher MR selectivity and a different MR conformational change upon binding; FIDELIO-DKD demonstrated 18% reduction in the primary renal composite endpoint in type 2 diabetes with CKD (eGFR 25–75 mL/min/1.73m2, UACR ≥300 mg/g) on background maximum tolerated RAAS inhibition; the evidence is strongest for type 2 diabetic CKD with persistent albuminuria despite optimized RAAS inhibition and SGLT2 inhibitors
D) Finerenone is a RAAS inhibitor that blocks aldosterone synthesis in the adrenal cortex rather than blocking the mineralocorticoid receptor — this upstream mechanism prevents aldosterone-driven fibrosis more completely than receptor blockade; it is the preferred agent for reducing hyperkalemia risk because blocking aldosterone synthesis prevents the aldosterone-mediated potassium retention that spironolactone causes
E) Finerenone is approved as first-line monotherapy for hypertension in all CKD stages — it is superior to RAAS inhibitors for BP control in CKD because its MR-blocking mechanism specifically addresses the aldosterone excess that drives CKD-related hypertension; the evidence from FIDELIO-DKD supports finerenone as the initial antihypertensive rather than an add-on therapy
ANSWER: C
Rationale:
Finerenone represents a pharmacologically distinct generation of mineralocorticoid receptor antagonism. Unlike spironolactone (a steroidal MRA with off-target androgen and progesterone receptor binding causing gynecomastia, sexual dysfunction, and menstrual irregularities) and eplerenone (a selective steroidal MRA with fewer sex hormone effects but lower potency per mg and shorter duration requiring twice-daily dosing), finerenone has a non-steroidal chemical scaffold that confers several pharmacological advantages. Its non-steroidal structure provides high selectivity for the MR receptor without affinity for androgen, progesterone, or glucocorticoid receptors, eliminating the hormonal adverse effects. Its binding to the MR also induces a distinct conformational change compared to steroidal MRAs — potentially recruiting different coregulatory proteins and producing anti-fibrotic and anti-inflammatory effects with a different tissue distribution profile (higher cardiac and renal tissue penetration). FIDELIO-DKD enrolled 5,734 patients with type 2 diabetes and CKD (eGFR 25–75 mL/min/1.73m2, UACR ≥300 mg/g) on background maximum tolerated RAAS inhibition. Finerenone produced 18% reduction in the primary renal composite endpoint and 14% reduction in the cardiovascular composite endpoint compared to placebo. FIGARO-DKD enrolled the lower albuminuria range (UACR 30–300 mg/g) and demonstrated cardiovascular benefit. The pooled FIDELITY analysis confirmed consistent benefit across the full spectrum. Current guidelines recommend finerenone as add-on therapy (not monotherapy) in eligible type 2 diabetic CKD patients with persistent albuminuria despite optimized RAAS inhibition and SGLT2 inhibitor use.
Option A: Option A is incorrect because finerenone is an MRA, not a loop diuretic with NKCC2-blocking properties.
Option B: Option B is incorrect because finerenone is chemically non-steroidal while eplerenone is steroidal — they are pharmacologically distinct.
Option D: Option D is incorrect because finerenone blocks the mineralocorticoid receptor, not aldosterone synthesis.
Option E: Option E is incorrect because finerenone is approved and studied as add-on therapy to RAAS inhibition, not as first-line monotherapy.
11. Which of the following most accurately explains the "sick day guidance" that should be provided to patients with CKD who are on RAAS inhibitors and diuretics, and the pharmacological basis for this advice?
A) Patients on RAAS inhibitors and diuretics should double their medication doses during acute illness to compensate for the increased fluid losses from vomiting or diarrhea — higher drug levels will maintain better blood pressure control during the stress response, which otherwise causes rebound hypertension
B) Patients should continue all antihypertensives unchanged during acute illness — the risks of stopping medications even temporarily outweigh any potential benefit; blood pressure rises during acute illness and antihypertensives are more important during these periods
C) Patients should hold only their diuretic during acute illness — RAAS inhibitors should be continued because their renoprotective efferent arteriolar effect is most needed when the kidney is stressed; diuretics cause volume depletion that is harmful during illness but RAAS inhibitors do not
D) Sick day guidance applies only to patients with CKD stage 4 and 5 — patients with stage 1 through 3 CKD have sufficient renal reserve to handle the combination of RAAS inhibitors plus diuretics during acute illness without AKI risk; no medication holds are needed at these stages
E) Patients with CKD on RAAS inhibitors and diuretics should temporarily hold both drug classes during acute illnesses involving significant volume depletion (vomiting, diarrhea, high fever with poor oral intake, surgical procedures) — the pharmacological basis is the triple whammy AKI risk: volume depletion from illness reduces renal perfusion pressure; diuretics further reduce intravascular volume; RAAS inhibitors remove the efferent arteriolar constriction that normally maintains intraglomerular pressure when systemic perfusion is reduced; the combination of reduced renal perfusion plus impaired autoregulatory response creates conditions for acute kidney injury that is often preventable; patients should be given explicit written sick day instructions and counseled to hold these medications for 24–48 hours when unable to maintain oral intake, resuming when clinical recovery occurs
ANSWER: E
Rationale:
Sick day guidance is a critically important but frequently overlooked component of CKD and hypertension management. The pharmacological basis involves understanding what happens when volume depletion is superimposed on a patient taking RAAS inhibitors and diuretics. Under normal hemodynamic conditions, renal autoregulation (including angiotensin II-mediated efferent arteriolar constriction) maintains intraglomerular GFR pressure over a range of systemic blood pressures. During acute illness with significant volume depletion (vomiting, diarrhea, high fever with poor intake), renal perfusion pressure falls. The kidney's normal autoregulatory response — increasing efferent arteriolar constriction via angiotensin II to maintain intraglomerular pressure — is specifically blocked by RAAS inhibitors. The diuretic simultaneously reduces intravascular volume further. The result is the "triple whammy" AKI: reduced perfusion pressure (illness) plus impaired autoregulation (RAAS inhibitor) plus reduced volume (diuretic). This combination can cause rapid AKI that is often preventable by temporarily holding the offending drugs during the vulnerable period. KDIGO and ADA guidelines recommend explicit sick day counseling for all patients on RAAS inhibitors and diuretics. The medications should be restarted once clinical recovery and adequate oral intake are established.
Option A: Option A is incorrect because increasing doses during illness amplifies the AKI risk rather than protecting against it.
Option B: Option B is incorrect because continuing RAAS inhibitors and diuretics during significant volume depletion is a known and preventable cause of AKI in CKD.
Option C: Option C is incorrect because the RAAS inhibitor's removal of efferent arteriolar protection is the central mechanism of sick-day AKI; holding only the diuretic is insufficient.
Option D: Option D is incorrect because the triple whammy AKI risk applies across all CKD stages, though the absolute risk is higher at more advanced stages.
12. Which of the following most accurately identifies the preferred ACEi and ARB for use in CKD stage 4 (eGFR 15–29 mL/min/1.73m2), and the pharmacological rationale for these preferences?
A) Lisinopril is the preferred ACEi in stage 4 CKD because its hydrophilicity prevents it from entering tubular cells, eliminating the nephrotoxic tubular accumulation seen with lipophilic ACEi; enalapril is the preferred ARB because its prodrug activation is unaffected by reduced GFR
B) Fosinopril is the preferred ACEi in stage 4 CKD because it has dual elimination — approximately 50% renal and 50% hepatic — meaning that as renal elimination declines, hepatic elimination compensates, preventing accumulation without requiring dose adjustment; telmisartan is the preferred ARB because it is eliminated primarily via biliary excretion rather than renal excretion, similarly avoiding accumulation in advanced renal failure
C) Ramipril is the preferred ACEi in stage 4 CKD because its active metabolite ramiprilat is eliminated exclusively by the liver — no renal elimination occurs; losartan is preferred because its active metabolite EXP-3174 is entirely hepatically inactivated with no renal component
D) Captopril is preferred in stage 4 CKD because its short half-life allows rapid dose titration if AKI occurs — the drug is cleared within 2–4 hours of the last dose, providing a safety margin not available with longer-acting agents; candesartan is the preferred ARB because it is activated during intestinal absorption without any renal metabolic step
E) Enalapril is the preferred ACEi in stage 4 CKD because enalaprilat (its active metabolite) accumulates in renal tubular cells at reduced GFR, producing prolonged drug effect with less frequent dosing and fewer systemic adverse effects; olmesartan is the preferred ARB because its biliary excretion is enhanced in CKD through compensatory upregulation of hepatic transporters
ANSWER: B
Rationale:
Drug accumulation in advanced CKD is a major safety concern for antihypertensives that rely on renal elimination. For ACEi in stage 4 CKD, fosinopril has a distinct pharmacokinetic advantage: it has dual elimination pathways (approximately 50% renal, 50% hepatic via biliary excretion). As GFR declines, hepatic elimination compensates — the total clearance of fosinoprilat (the active diacid metabolite) is maintained reasonably well even at eGFR 15–29 mL/min/1.73m2, without the accumulation seen with primarily renally eliminated ACEi (enalapril, lisinopril, ramipril). For ARBs, telmisartan is preferred at advanced CKD because its elimination is almost entirely via biliary excretion — it is not significantly renally eliminated and does not accumulate in CKD. This pharmacokinetic advantage makes telmisartan the preferred ARB in stage 4 CKD when continued RAAS inhibition is clinically justified. Candesartan and losartan undergo partial renal elimination and require more careful monitoring at this eGFR.
Option A: Option A is incorrect because enalapril is not an ARB — it is an ACEi prodrug; and lisinopril is primarily renally eliminated, accumulating in advanced CKD.
Option C: Option C is incorrect because ramiprilat (the active metabolite of ramipril) does have significant renal elimination and can accumulate in advanced CKD; and losartan's active metabolite EXP-3174 does have some renal elimination component.
Option D: Option D is incorrect because captopril's short half-life is not its primary advantage for CKD — it is primarily renally eliminated and accumulates in advanced CKD.
Option E: Option E is incorrect because enalaprilat accumulation in tubular cells is a safety concern, not an advantage; and olmesartan's biliary excretion is not specifically upregulated in CKD.
13. A 68-year-old man with CKD stage 4 (eGFR 22 mL/min/1.73m2), hypertension, and no diabetes requires an additional antihypertensive agent. He is currently on telmisartan 80 mg and amlodipine 10 mg daily with BP 152/90 mmHg. His potassium is 5.2 mEq/L. Which of the following most accurately identifies the appropriate next antihypertensive and the considerations specific to CKD stage 4?
A) Add spironolactone 25 mg daily — despite the potassium of 5.2 mEq/L, spironolactone's renoprotective anti-fibrotic effect in stage 4 CKD outweighs the hyperkalemia risk when combined with potassium monitoring every 2 weeks
B) Add chlorthalidone 12.5 mg daily — thiazide-type diuretics retain full antihypertensive efficacy at eGFR 22 mL/min/1.73m2 and provide superior 24-hour coverage compared to loop diuretics in advanced CKD
C) Add atenolol 25 mg daily — atenolol is the preferred beta-blocker in CKD stage 4 because its hydrophilicity prevents CNS side effects; dose adjustment is not needed at eGFR 22 mL/min/1.73m2
D) Switch to torsemide 20 mg daily as a loop diuretic and add bisoprolol 2.5 mg daily — at eGFR 22 mL/min/1.73m2 (stage 4 CKD), a loop diuretic is the appropriate diuretic class for volume management as thiazide-type diuretics are substantially ineffective at this eGFR; bisoprolol is preferred over atenolol as an add-on beta-blocker because bisoprolol has dual renal and hepatic elimination (~50% each), providing more predictable plasma levels in advanced CKD compared to atenolol which accumulates significantly due to its primarily renal elimination; potassium of 5.2 mEq/L argues against adding an MRA; an MRA should not be added with concurrent telmisartan and potassium already above 5.0 mEq/L
E) Add lisinopril 5 mg daily — dual RAAS blockade with telmisartan plus lisinopril provides the most complete RAAS suppression and is particularly effective in stage 4 CKD where aldosterone breakthrough from the ARB is common; the potassium is not yet at the threshold requiring withholding the second RAAS inhibitor
ANSWER: D
Rationale:
This patient at eGFR 22 mL/min/1.73m2 (stage 4 CKD) requires careful drug selection considering the pharmacokinetics of each class at advanced renal failure. A loop diuretic is the appropriate diuretic class at this eGFR — torsemide is preferred over furosemide for its approximately 80% predictable oral bioavailability compared to furosemide's highly variable absorption (10–100%). This addresses both volume management and blood pressure control. A beta-blocker can be added for additional BP reduction; bisoprolol is preferred over atenolol specifically because of atenolol's pharmacokinetic profile in CKD: atenolol is approximately 85–90% renally eliminated, accumulating significantly at eGFR 22 mL/min/1.73m2 and requiring dose adjustment; failure to adjust the dose can lead to excessive beta-blockade (bradycardia, AV block, bronchospasm). Bisoprolol's dual elimination (~50% renal, ~50% hepatic) maintains more predictable plasma levels in advanced CKD. Spironolactone with potassium of 5.2 mEq/L and concurrent telmisartan (which conserves potassium) would create high hyperkalemia risk — this is a contraindication.
Option A: Option A is incorrect because potassium of 5.2 mEq/L with concurrent ARB is a contraindication to spironolactone in stage 4 CKD.
Option B: Option B is incorrect because thiazide-type diuretics have substantially reduced efficacy at eGFR 22 mL/min/1.73m2; a loop diuretic is needed.
Option C: Option C is incorrect because atenolol accumulates significantly in stage 4 CKD due to primarily renal elimination — dose adjustment is required and it is less preferred than bisoprolol.
Option E: Option E is incorrect because dual RAAS blockade (telmisartan plus lisinopril) is contraindicated by VA NEPHRON-D and KDIGO evidence — it produces excess AKI and hyperkalemia without additional benefit.
14. A 52-year-old woman with type 2 diabetes, CKD stage 3b (eGFR 36 mL/min/1.73m2, UACR 520 mg/g), and hypertension (BP 148/88 mmHg) is currently on metformin 500 mg twice daily, losartan 100 mg daily, and amlodipine 10 mg daily. Potassium is 4.4 mEq/L. Her endocrinologist wants to initiate an SGLT2 inhibitor and her nephrologist wants to add finerenone. Her primary care physician asks whether both additions are pharmacologically appropriate and what the correct sequence should be.
Which of the following most accurately evaluates the appropriateness of both additions and the sequencing?
A) Both additions are pharmacologically appropriate for this patient — the combination of RAAS inhibitor plus SGLT2 inhibitor plus finerenone represents the emerging "triple combination" for type 2 diabetic CKD supported by FIDELITY pooled analysis data; the SGLT2 inhibitor (dapagliflozin or empagliflozin) should be added first because its renal outcome evidence is established at eGFR as low as 25 mL/min/1.73m2, its tolerability is well-documented on background RAAS inhibition, and it may lower potassium modestly through osmotic diuresis (creating favorable conditions for finerenone); finerenone should be added second after confirming potassium response and SGLT2 inhibitor tolerability; metformin at eGFR 36 mL/min/1.73m2 is at the lower boundary for continued use and should be reviewed — most guidelines recommend holding or discontinuing metformin below eGFR 30 mL/min/1.73m2
B) Only the SGLT2 inhibitor should be added — finerenone is contraindicated when an ARB is already prescribed because the combination constitutes a prohibited form of dual RAAS blockade; the ARB must be discontinued before finerenone can be initiated
C) Only finerenone should be added — SGLT2 inhibitors are contraindicated at eGFR below 45 mL/min/1.73m2 for any indication including renal protection; the glycosuria mechanism requires a minimum GFR threshold to produce meaningful glucose excretion
D) Neither addition is appropriate at this eGFR — both SGLT2 inhibitors and finerenone are approved only for CKD stage 1 and 2 (eGFR above 60 mL/min/1.73m2); at eGFR 36 mL/min/1.73m2, standard antihypertensive intensification (adding a diuretic or beta-blocker) is the only guideline-supported approach
E) The SGLT2 inhibitor is contraindicated because this patient is already on an ARB — combining an ARB with an SGLT2 inhibitor constitutes prohibited dual volume depletion through two additive mechanisms (ARB-mediated natriuresis and SGLT2 inhibitor-mediated osmotic diuresis); the combination increases AKI risk beyond acceptable limits
ANSWER: A
Rationale:
This patient has the clinical profile that most strongly supports both additions. Her eGFR of 36 mL/min/1.73m2 falls within the enrollment range of both DAPA-CKD (eGFR 25–75 mL/min/1.73m2) and FIDELIO-DKD (eGFR 25–75 mL/min/1.73m2), and her UACR of 520 mg/g with type 2 diabetes represents the highest-risk phenotype with the strongest evidence for benefit from both agents. The SGLT2 inhibitor should be added first: DAPA-CKD demonstrated robust benefit at this eGFR range in patients with type 2 diabetes; the SGLT2 inhibitor's osmotic diuresis and natriuresis may modestly lower potassium (helping create conditions for the safe introduction of finerenone); and it is well-tolerated on background RAAS inhibition without the potassium concerns of an MRA. Finerenone is then added once SGLT2 inhibitor tolerability and potassium response are confirmed. This sequence is now endorsed by emerging KDIGO 2022 diabetes management guidelines that recommend RAAS inhibitor + SGLT2 inhibitor + finerenone as the triple combination in eligible type 2 diabetic CKD. The metformin flag is clinically important — most guidelines recommend discontinuation at eGFR below 30 mL/min/1.73m2 and increased caution below 45 mL/min/1.73m2; with eGFR at 36, it should be reviewed and the dose may need reduction.
Option B: Option B is incorrect because finerenone is an MRA, not a RAAS inhibitor — it does not constitute dual RAAS blockade when combined with an ARB; its combination with RAAS inhibitors was specifically studied in FIDELIO-DKD.
Option C: Option C is incorrect because SGLT2 inhibitors' renal indication has been established at eGFR as low as 20–25 mL/min/1.73m2 — the glycosuria threshold for renal protection is not the relevant eGFR limitation.
Option D: Option D is incorrect because both agents have trials enrolling patients with eGFR as low as 25 mL/min/1.73m2.
Option E: Option E is incorrect because ARBs work through neurohormonal (not natriuretic) mechanisms and combining them with SGLT2 inhibitors is standard of care in diabetic CKD — the combination is not pharmacologically prohibited.
15. A 74-year-old man with CKD stage 5 on hemodialysis three times per week has BP 168/96 mmHg on clinic days and 148/88 mmHg on dialysis days. His interdialytic weight gain averages 3.8 kg. He is currently on amlodipine 10 mg and lisinopril 5 mg daily. His nephrologist notes that lisinopril is significantly removed by hemodialysis sessions.
Which of the following most accurately describes the pharmacological approach to managing hypertension in this hemodialysis patient and the implications of dialyzability?
A) Lisinopril should be maintained at 5 mg daily — the amount removed by hemodialysis is clinically insignificant and has no effect on the antihypertensive action; the primary management strategy should be increasing the lisinopril dose to 20 mg daily to achieve adequate 24-hour BP control
B) Lisinopril should be discontinued and replaced with a non-antihypertensive strategy — all ACEi and ARBs are contraindicated in hemodialysis patients because residual renal function is absent and RAAS inhibitors can only act through renal mechanisms that are no longer present; no renoprotective benefit is possible in ESRD
C) The interdialytic weight gain of 3.8 kg indicates that volume control through ultrafiltration and dietary sodium restriction is the dominant and most important blood pressure management strategy in this patient; regarding lisinopril's dialyzability — lisinopril and enalapril are significantly removed by hemodialysis, potentially requiring supplemental post-dialysis dosing to maintain 24-hour coverage; telmisartan or candesartan are preferred ARBs in hemodialysis patients because they are not significantly dialyzed; the high interdialytic BP (168/96 mmHg) primarily reflects volume expansion from interdialytic weight gain rather than inadequate antihypertensive dosing, making fluid and sodium management the priority
D) The primary management strategy is to switch lisinopril to atenolol — atenolol is the preferred antihypertensive in hemodialysis because it is also removed by dialysis, thereby synchronizing its removal with the volume removal that occurs during ultrafiltration and producing coordinated hemodynamic management
E) The dialysis prescription should be changed to daily nocturnal hemodialysis immediately — the BP of 168/96 mmHg on clinic days confirms that thrice-weekly dialysis is pharmacologically insufficient; pharmacological antihypertensives should be discontinued until the dialysis modality is changed
ANSWER: C
Rationale:
Hypertension management in hemodialysis patients differs fundamentally from pre-dialysis CKD management. Volume control is the dominant mechanism of BP management in ESRD on hemodialysis — the interdialytic accumulation of sodium and fluid is the primary driver of between-session hypertension, and ultrafiltration (the removal of this excess volume during dialysis sessions) is the most effective antihypertensive intervention. This patient's interdialytic weight gain of 3.8 kg is substantial and is the primary explanation for the high clinic-day BP (168/96 mmHg) — this represents volume that was not removed during the previous dialysis session. The pharmacological implication is that dietary sodium restriction (targeting less than 2 g/day) and achieving dry weight (the post-dialysis weight at which the patient is euvolemic) are more important than dose adjustments of antihypertensives. Regarding RAAS inhibitor selection in hemodialysis: lisinopril and enalapril are significantly removed by high-flux hemodialysis membranes, creating a pharmacokinetic problem — the drug is cleared during the dialysis session that also removes fluid, potentially leaving the patient inadequately covered in the interdialytic period when BP is highest. Telmisartan and candesartan are not significantly dialyzed and maintain interdialytic coverage — making them pharmacologically preferred in hemodialysis patients who require RAAS inhibition for cardiovascular protection.
Option A: Option A is incorrect because dialyzability is clinically significant — lisinopril removal during dialysis can compromise interdialytic BP control.
Option B: Option B is incorrect because RAAS inhibitors provide cardiovascular (not purely renoprotective) benefit in ESRD patients, including reduction of cardiovascular events.
Option D: Option D is incorrect because atenolol's dialyzability is not a desired property that synchronizes with ultrafiltration — it creates gaps in beta-blockade during the interdialytic period.
Option E: Option E is incorrect because switching to daily nocturnal dialysis is not the first-line response to inadequate volume control; dietary modification and optimization of the existing prescription are the initial approach.
16. Which of the following most accurately describes the CLICK trial's contribution to the evidence base for thiazide-type diuretic use in CKD, and what clinical practice implication it established?
A) The CLICK trial demonstrated that chlorthalidone was equally effective as furosemide for blood pressure control in CKD stage 3 and 4, establishing chlorthalidone as the preferred diuretic across all CKD stages and eliminating the need to transition to loop diuretics in advanced CKD
B) The CLICK trial demonstrated that chlorthalidone was ineffective in CKD stage 3 and 4 and caused excess hyperkalemia, definitively establishing that thiazide-type diuretics should not be used below eGFR 60 mL/min/1.73m2
C) The CLICK trial compared chlorthalidone to placebo in patients with CKD stage 5 on hemodialysis — it demonstrated that chlorthalidone 25 mg three times weekly (given on dialysis days) reduced interdialytic weight gain and improved BP control, establishing a role for thiazide diuretics even in ESRD
D) The CLICK trial demonstrated that HCTZ 25 mg was superior to chlorthalidone 12.5 mg for BP control in CKD stage 3, establishing HCTZ as the preferred thiazide-type diuretic when eGFR is 30–60 mL/min/1.73m2 because its shorter half-life produces more predictable diuresis without overnight accumulation
E) The CLICK trial randomized patients with CKD stage 3 and 4 (on background RAAS inhibition) to chlorthalidone 12.5–25 mg versus placebo and demonstrated that chlorthalidone reduced 24-hour ambulatory systolic BP by approximately 11 mmHg versus placebo — a clinically meaningful reduction that established chlorthalidone as having meaningful antihypertensive activity even at eGFR as low as stage 4, supporting its continued use as an add-on antihypertensive in CKD patients on RAAS inhibition when eGFR permits; this challenged the perception that thiazides lose all efficacy before eGFR reaches 30 mL/min/1.73m2
ANSWER: E
Rationale:
The CLICK trial (Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease) addressed a critical knowledge gap — whether thiazide-type diuretics retain clinically meaningful antihypertensive activity in patients with advanced CKD who are already on background RAAS inhibition. Prior to CLICK, conventional teaching held that thiazide efficacy was essentially lost below eGFR 30–45 mL/min/1.73m2, leading many clinicians to avoid or discontinue thiazides in CKD stage 3b and 4. CLICK enrolled patients with CKD stage 3 and 4 (eGFR ranging from approximately 15–45 mL/min/1.73m2) who had uncontrolled hypertension on optimized background therapy including RAAS inhibition and randomized them to chlorthalidone 12.5–25 mg versus placebo. The primary outcome — change in 24-hour ambulatory systolic BP — showed an approximately 11 mmHg reduction with chlorthalidone versus placebo. This was a substantial and clinically meaningful reduction, establishing that chlorthalidone retains meaningful antihypertensive activity even in advanced CKD. The CLICK trial therefore challenged the absolute prohibition on thiazide use in advanced CKD and supported continued use of chlorthalidone as an add-on agent — particularly on background of RAAS inhibition where the complementary mechanisms (RAAS inhibition addressing neurohormonal vasoconstriction, chlorthalidone addressing volume) are maintained. Loop diuretics remain the primary volume management diuretic at advanced CKD stages, but the CLICK data indicates that chlorthalidone provides additive antihypertensive benefit when loop diuretics alone do not achieve target BP.
Option A: Option A is incorrect because CLICK compared chlorthalidone to placebo, not to furosemide.
Option B: Option B is incorrect because CLICK demonstrated meaningful BP reduction with chlorthalidone in advanced CKD — the opposite of finding it ineffective.
Option C: Option C is incorrect because CLICK enrolled pre-dialysis patients (CKD stage 3–4), not ESRD patients on hemodialysis.
Option D: Option D is incorrect because CLICK used chlorthalidone, not HCTZ, and chlorthalidone was the study drug — not HCTZ.
17. Which of the following most accurately explains why dietary sodium restriction significantly enhances the antiproteinuric response to RAAS inhibitors in patients with CKD, and what monitoring parameter confirms this interaction?
A) Dietary sodium restriction enhances RAAS inhibitor efficacy by increasing plasma sodium concentration, which amplifies AT1 receptor sensitivity to angiotensin II blockade — the higher the serum sodium, the greater the antiproteinuric response to the same ACEi or ARB dose; serum sodium should be monitored to confirm this enhancement
B) Dietary sodium restriction enhances the antiproteinuric response to RAAS inhibitors by reducing the competing stimulus for efferent arteriolar constriction — when sodium intake is high, the macula densa senses adequate distal sodium delivery and suppresses renin, blunting the RAAS inhibitor's ability to reduce angiotensin II; with sodium restriction, volume contraction activates the RAAS more strongly, providing more substrate for the RAAS inhibitor to block; simultaneously, lower systemic BP reduces the intraglomerular pressure driving proteinuria; the interaction is confirmed by monitoring 24-hour urine sodium (target below 100 mmol/day, equivalent to below 2.3 g sodium/day) alongside serial UACR measurements
C) Dietary sodium restriction enhances RAAS inhibitor antiproteinuric efficacy through direct tubular effects — sodium restriction downregulates the sodium-potassium ATPase in proximal tubular cells, reducing the energy available for active albumin reabsorption and therefore lowering the apparent proteinuria on dipstick testing; the monitoring parameter is serum sodium
D) Dietary sodium restriction is contraindicated with RAAS inhibitor therapy in CKD — the combination of RAAS inhibitor-mediated potassium retention and sodium restriction creates severe electrolyte imbalance; patients on RAAS inhibitors should follow a high-sodium diet to maintain adequate volume status
E) Dietary sodium restriction does not interact with RAAS inhibitor antiproteinuric efficacy — the two interventions have independent and additive but non-interacting effects on proteinuria; the combination reduces UACR by the sum of each individual reduction without any pharmacological synergy
ANSWER: B
Rationale:
The interaction between dietary sodium restriction and RAAS inhibitor antiproteinuric efficacy is well-established and clinically important. The mechanism involves two complementary pathways. First, high sodium intake suppresses the RAAS through volume expansion — high sodium delivery to the macula densa reduces renin secretion, lowering plasma angiotensin II levels. In this low-renin, high-volume state, there is less angiotensin II for RAAS inhibitors to block, blunting their efferent arteriolar dilating effect and their antiproteinuric efficacy. Sodium restriction activates the RAAS through volume contraction, increasing plasma angiotensin II and providing more substrate for the RAAS inhibitor to block — amplifying the efferent arteriolar dilation and proteinuria reduction. Second, sodium restriction independently reduces systemic blood pressure, further reducing the intraglomerular pressure driving proteinuria. The clinical consequence is that patients who maintain a high sodium diet despite RAAS inhibitor therapy will have a substantially attenuated antiproteinuric response — sometimes appearing to be "non-responders" when the true issue is inadequate sodium restriction. Confirming dietary sodium restriction through 24-hour urine sodium collection (target below 100 mmol/day, equivalent to approximately below 2.3 g sodium/day) is the key monitoring parameter, alongside serial UACR measurements showing the expected antiproteinuric response.
Option A: Option A is incorrect because serum sodium does not directly predict AT1 receptor sensitivity; the mechanism is renin-angiotensin activation from volume contraction, not plasma sodium concentration.
Option C: Option C is incorrect because the mechanism involves intraglomerular hemodynamics and RAAS activation, not tubular albumin reabsorption energetics.
Option D: Option D is incorrect because dietary sodium restriction in combination with RAAS inhibitors is standard of care and evidence-based — it enhances, not compromises, the antiproteinuric response.
Option E: Option E is incorrect because the interaction is pharmacologically synergistic, not merely additive — sodium restriction amplifies the RAAS substrate available for inhibition.
18. Which of the following most accurately identifies the J-curve concern specific to CKD patients with established coronary artery disease, and how it should influence blood pressure target decision-making?
A) The J-curve concern does not apply to CKD patients — renal autoregulation is so severely impaired in CKD that both very high and very low BP are uniformly harmful, eliminating any J-shaped relationship; the lowest achievable BP is always the safest target in CKD regardless of diastolic BP level
B) The J-curve concern applies exclusively to systolic blood pressure in CKD — diastolic BP has no relationship to cardiovascular outcomes in CKD patients; only systolic targets should be pursued and diastolic BP should be disregarded when titrating antihypertensives
C) The J-curve concern in CKD is identical to that in the general population — diastolic BP below 90 mmHg is associated with increased mortality in all hypertensive patients including those with CKD; the target diastolic BP in CKD should therefore be maintained between 90 and 100 mmHg to avoid J-curve harm
D) The J-curve concern in CKD patients with established coronary artery disease involves the diastolic blood pressure — coronary perfusion occurs predominantly during diastole through the relaxed myocardium; when diastolic BP is reduced below approximately 65–70 mmHg, coronary perfusion pressure may be inadequate, particularly in patients with fixed coronary stenoses; the practical implications are to avoid over-aggressive antihypertensive titration in older CKD patients with CAD when diastolic BP approaches this range, monitor for symptoms of coronary hypoperfusion (angina, dyspnea), and individualize targets in frail elderly patients who may not tolerate the intensive systolic targets achieved in clinical trials
E) The J-curve concern in CKD is limited to renal outcomes — excessive BP lowering reduces renal perfusion pressure to below the impaired autoregulatory range in CKD nephrons, causing AKI; cardiovascular J-curve concerns do not apply because CKD-related cardiac hypertrophy creates a protected left ventricular oxygen supply
ANSWER: D
Rationale:
The J-curve phenomenon — where both very high and very low blood pressure are associated with increased cardiovascular risk, producing a J-shaped relationship rather than a linear one — is particularly relevant to CKD patients with comorbid coronary artery disease. The physiological basis is diastolic coronary perfusion: unlike most other organs (where blood flow is continuous throughout the cardiac cycle), the left ventricular myocardium is perfused predominantly during diastole. During systole, myocardial contraction compresses the coronary microcirculation, essentially interrupting flow; during diastole, myocardial relaxation allows coronary blood flow driven by the aortic diastolic pressure. When diastolic BP is reduced below approximately 65–70 mmHg in patients with established coronary artery disease — particularly those with fixed stenoses that require higher perfusion pressures to maintain adequate distal flow — coronary hypoperfusion can occur, potentially causing subendocardial ischemia or destabilizing angina. In CKD patients with CAD (a very common comorbidity given CKD's cardiovascular risk burden), this J-curve concern is clinically meaningful. The practical implications are: individualize BP targets; avoid over-aggressive antihypertensive titration when diastolic BP approaches 65–70 mmHg in patients with established CAD; monitor for symptoms of coronary hypoperfusion during titration; and be particularly cautious in frail elderly patients who may not tolerate the intensive targets used in clinical trials (which typically excluded very elderly or frail patients).
Option A: Option A is incorrect because the J-curve concern does apply in CKD, particularly for patients with comorbid CAD.
Option B: Option B is incorrect because diastolic BP — specifically its reduction below coronary perfusion pressure thresholds — is the primary J-curve concern in patients with CAD.
Option C: Option C is incorrect because the J-curve concern specifically applies to diastolic BP below 65–70 mmHg in patients with CAD, not diastolic BP below 90 mmHg in all hypertensives.
Option E: Option E is incorrect because the cardiovascular J-curve concern in CKD is well-recognized and not limited to renal outcomes.
19. Which of the following most accurately describes the REIN trial's contribution to establishing ACEi renoprotection in non-diabetic CKD, and the specific feature of its findings that had the greatest clinical impact?
A) The REIN trial (ramipril versus placebo in non-diabetic proteinuric CKD) demonstrated that ramipril significantly reduced the rate of GFR decline and the risk of reaching ESRD; the most clinically impactful finding was that the renoprotective benefit was greatest in patients with the highest baseline proteinuria — patients with proteinuria above 3 g/day showed the most dramatic slowing of CKD progression, establishing baseline proteinuria as a predictor of both CKD progression risk and the magnitude of RAAS inhibitor renoprotective benefit; this confirmed that antiproteinuric therapy is most urgently needed (and most beneficial) in those with the heaviest proteinuric burden
B) The REIN trial demonstrated that ramipril reduced the rate of GFR decline in non-diabetic CKD but provided no reduction in ESRD risk — the GFR stabilization effect was clinically meaningful but the lack of ESRD reduction meant that REIN could not support RAAS inhibitor use as a renal endpoint-modifying therapy
C) The REIN trial demonstrated that both ramipril and amlodipine were equally effective at slowing non-diabetic CKD progression when systemic BP was equivalently controlled, establishing that systemic BP reduction is the sole mechanism of renoprotection in non-diabetic CKD
D) The REIN trial enrolled only patients with polycystic kidney disease and IgA nephropathy — it was the first trial to demonstrate RAAS inhibitor benefit in specific glomerular diseases; its findings cannot be generalized to hypertensive nephrosclerosis or diabetic nephropathy
E) The REIN trial was a placebo-controlled trial demonstrating that higher doses of ramipril provided no additional benefit over standard doses in non-diabetic proteinuric CKD; the optimal ACEi dose for non-diabetic CKD is the standard antihypertensive dose rather than the maximum tolerated dose
ANSWER: A
Rationale:
The REIN trial (Ramipril Efficacy in Nephropathy) enrolled patients with non-diabetic, proteinuric CKD and randomized them to ramipril versus placebo, with achieved blood pressure equivalence between groups. Ramipril significantly reduced the rate of GFR decline and the risk of reaching ESRD compared to placebo. The most clinically important finding from REIN was the dose-response relationship between baseline proteinuria and the magnitude of renoprotective benefit: patients with the highest baseline proteinuria (above 3 g/day) showed the greatest absolute benefit from ramipril — both the greatest reduction in GFR decline rate and the greatest reduction in ESRD risk. This finding had profound clinical implications: it established that baseline proteinuria is not only a marker of CKD progression risk but also a predictor of the magnitude of RAAS inhibitor benefit — meaning the patients who most need antiproteinuric therapy are also the ones who benefit most from it. This supports the guideline recommendation for RAAS inhibitors in all CKD patients with albuminuria above 30 mg/g (Category A evidence), with the recommendation strongest for those with albuminuria above 300 mg/g. It also established the principle that maximizing antiproteinuric response (through dose titration and dietary sodium restriction) is a key treatment goal, not just BP control.
Option B: Option B is incorrect because REIN demonstrated reduction in both GFR decline rate and ESRD risk.
Option C: Option C is incorrect because REIN compared ramipril to placebo, not to amlodipine; the IDNT trial made the ramipril versus CCB comparison in diabetic nephropathy.
Option D: Option D is incorrect because REIN enrolled patients with various forms of non-diabetic proteinuric CKD including diabetic nephropathy-like conditions — not exclusively polycystic kidney disease or IgA nephropathy.
Option E: Option E is incorrect about the trial's design — REIN tested ramipril versus placebo, not low dose versus high dose.
20. Which of the following most accurately describes how hypertension management should differ between a CKD patient with significant albuminuria (UACR 450 mg/g) and a CKD patient without albuminuria (UACR below 30 mg/g) at the same eGFR of 45 mL/min/1.73m2?
A) The management is identical for both patients — KDIGO 2021 recommends ACEi or ARB as first-line therapy for all patients with CKD regardless of albuminuria status; the UACR level affects only the BP target, not the drug class selection
B) The patient without albuminuria should receive RAAS inhibitors as first-line therapy while the patient with albuminuria should receive CCBs — UACR above 300 mg/g is a contraindication to RAAS inhibitors because proteinuria indicates the glomerular filtration barrier is already compromised and RAAS inhibitor-mediated efferent dilation would accelerate protein leakage
C) For the patient with significant albuminuria (UACR 450 mg/g), RAAS inhibition is the pharmacological cornerstone — ACEi or ARB should be initiated or continued regardless of whether the patient has diabetes, because the glomerular pressure reduction and antiproteinuric mechanisms of RAAS inhibitors directly target the proteinuria-fibrosis-progression axis; the patient without albuminuria (UACR below 30 mg/g) does not have the same compelling indication for RAAS inhibitors — standard antihypertensive therapy (CCB, thiazide-like diuretic) applies to both, but RAAS inhibitors are specifically indicated by the albuminuria and can be selected from other classes in the non-albuminuric patient based on comorbidities and tolerability; both patients share the same BP target (below 130/80 mmHg per ACC/AHA 2017)
D) Both patients should receive identical first-line therapy with CCBs plus thiazide-type diuretics — RAAS inhibitors are only indicated in CKD when proteinuria exceeds 3.5 g/day (nephrotic-range proteinuria); moderate proteinuria of 450 mg/g does not meet the threshold for RAAS inhibitor-specific indication in CKD
E) The patient with albuminuria requires a more aggressive systolic BP target (below 110 mmHg) than the patient without albuminuria (below 130 mmHg) — the UACR level directly determines the BP target, with each 100 mg/g increase in UACR requiring a 5 mmHg lower systolic target
ANSWER: C
Rationale:
KDIGO 2021 blood pressure guidelines and the broader pharmacological evidence base make albuminuria the central determinant of RAAS inhibitor indication in CKD. For a patient with CKD and significant albuminuria (UACR above 30 mg/g, and especially above 300 mg/g), ACEi or ARB therapy is strongly recommended as the antihypertensive foundation regardless of diabetes status — because the glomerular pressure-reducing and antiproteinuric mechanisms directly target the primary drivers of CKD progression. The antiproteinuric response (confirmed at 3 months) should guide RAAS inhibitor dose titration. For a patient with CKD at the same eGFR but without albuminuria (UACR below 30 mg/g), the compelling proteinuria-driven indication for RAAS inhibition is absent. Standard antihypertensive classes — CCBs, thiazide-like diuretics, beta-blockers with appropriate renal dosing — apply. RAAS inhibitors are still acceptable and may be preferred if other compelling indications are present (diabetes, heart failure, post-MI), but they are not specifically mandated by the CKD alone. Both patients share the same systolic BP target per ACC/AHA 2017 (below 130/80 mmHg); KDIGO 2021's below-120 mmHg target (using AOBP methodology) also applies to both.
Option A: Option A is incorrect because KDIGO 2021 recommends ACEi or ARB for CKD with albuminuria above 30 mg/g but does not mandate them for CKD without albuminuria — the albuminuria status significantly differentiates the indication.
Option B: Option B is incorrect because albuminuria above 300 mg/g is the strongest indication for RAAS inhibitors, not a contraindication — the mechanism reduces glomerular pressure and proteinuria.
Option D: Option D is incorrect because the indication for RAAS inhibitors in CKD is albuminuria above 30 mg/g — not nephrotic-range proteinuria (3.5 g/day) as the sole threshold.
Option E: Option E is incorrect because BP targets are not calculated as a mathematical function of UACR; they are categorical recommendations from clinical trial evidence.
21. Which of the following most accurately describes why torsemide is preferred over furosemide as the loop diuretic in CKD stage 4 and 5, and what clinical monitoring is essential when using loop diuretics at high doses in advanced CKD?
A) Torsemide is preferred over furosemide because torsemide is renally eliminated while furosemide is hepatically metabolized — renal elimination provides a self-regulating mechanism where declining GFR automatically reduces torsemide levels, preventing accumulation; furosemide accumulates in CKD due to impaired hepatic metabolism
B) Torsemide is preferred over furosemide because torsemide has a longer half-life that requires once-weekly dosing in stage 4 CKD, reducing pill burden and improving adherence; furosemide's twice-daily dosing creates compliance challenges in the CKD population
C) Torsemide is preferred over furosemide because torsemide is a thiazide-like diuretic in addition to its loop diuretic properties — it simultaneously inhibits both NKCC2 (thick ascending limb) and NCC (distal convoluted tubule), providing superior natriuresis at low eGFR; furosemide lacks the distal tubule component
D) Torsemide and furosemide are pharmacologically identical — there is no clinical basis for preferring torsemide over furosemide in CKD; the choice between them should be based solely on cost and formulary availability
E) Torsemide is preferred over furosemide in CKD because of its superior oral bioavailability — torsemide is absorbed with approximately 80% bioavailability that remains consistent regardless of GI conditions, whereas furosemide has highly variable oral bioavailability of 10–100% depending on gut edema, food intake, and GI motility; this variability in furosemide absorption creates unpredictable diuretic responses that complicate volume management in advanced CKD; essential monitoring when using loop diuretics at high doses in advanced CKD includes renal function (creatinine, eGFR), electrolytes (potassium, sodium, magnesium), and clinical assessment of volume status and residual urine output
ANSWER: E
Rationale:
The pharmacokinetic difference between torsemide and furosemide — specifically their oral bioavailability — is the primary clinical rationale for preferring torsemide in advanced CKD. Furosemide oral bioavailability is notoriously variable: it ranges from 10–100% (average approximately 50%) depending on multiple factors including gut wall edema (common in heart failure and advanced CKD with volume overload), GI motility, food intake, and individual absorption variation. In patients with CKD who may have concurrent gut edema or fluid retention, furosemide absorption can be severely impaired — leading to situations where a patient appears to be diuretic-resistant when the actual problem is inadequate drug absorption. Torsemide has predictably high oral bioavailability of approximately 80% that is not significantly affected by gut edema or food — making its diuretic response far more predictable and reproducible. This predictability is particularly important in advanced CKD where volume management is critical for BP control and symptom management. Clinically, this means that patients who appear refractory to furosemide often respond well when switched to torsemide at equivalent doses. Both loop diuretics act at NKCC2 in the thick ascending limb. Monitoring at high doses in advanced CKD includes: renal function (loop diuretics can cause pre-renal azotemia from volume depletion), electrolytes (potassium, sodium, and magnesium — loop diuretics are kaliuretic and magnesiuretic), and clinical volume assessment including body weight and residual urine output (preserving residual renal function is clinically important in pre-dialysis CKD).
Option A: Option A is incorrect because torsemide is primarily hepatically metabolized, while furosemide has a significant renal elimination component — this is the opposite of what is stated.
Option B: Option B is incorrect because torsemide requires once-daily (not once-weekly) dosing; this is an advantage over furosemide's typical twice-daily dosing.
Option C: Option C is incorrect because torsemide acts primarily at NKCC2 like other loop diuretics — it does not have thiazide-like NCC inhibitory properties.
Option D: Option D is incorrect because the oral bioavailability difference is a clinically significant pharmacological distinction.
22. A 60-year-old woman with CKD stage 3b (eGFR 34 mL/min/1.73m2, UACR 340 mg/g) and hypertension is well-controlled on losartan 100 mg and amlodipine 10 mg daily (BP 126/78 mmHg). She has no diabetes. Her potassium is 5.1 mEq/L. She returns to clinic after 3 weeks of a viral gastroenteritis episode during which she could not eat or drink normally and was vomiting for 4 days. Her creatinine has risen from 1.6 to 2.8 mg/dL. BP is 108/62 mmHg.
Which of the following most accurately identifies the likely diagnosis, mechanism, and appropriate management?
A) This is progression of her CKD from stage 3b to stage 4 — the viral illness unmasked accelerated CKD progression that was occurring subclinically; losartan should be permanently discontinued and the patient transitioned to hemodialysis planning; the low BP reflects end-stage renal failure with reduced cardiac output
B) This is acute kidney injury superimposed on CKD (AKI-on-CKD), most likely from the triple whammy mechanism: the viral illness caused significant volume depletion through vomiting and poor oral intake; amlodipine maintained vasodilation without the compensatory RAAS-mediated efferent arteriolar constriction; losartan blocked the efferent arteriolar constriction that normally maintains intraglomerular pressure when renal perfusion is reduced; the combination of reduced perfusion pressure plus impaired autoregulatory response caused AKI; immediate management is volume resuscitation (IV normal saline), temporary withholding of losartan and amlodipine until volume is restored and creatinine trends downward, then gradual re-introduction of the RAAS inhibitor once hemodynamic stability is confirmed; this AKI is expected to be largely reversible
C) This is contrast nephropathy from the intravenous contrast used during her recent CT scan — the history of viral illness is coincidental; N-acetylcysteine should be administered and losartan permanently discontinued as all RAAS inhibitors are contraindicated after contrast nephropathy
D) This is hyperkalemia-induced renal vasoconstriction — potassium of 5.1 mEq/L caused afferent arteriolar spasm, reducing GFR; immediate IV calcium gluconate is the first-line treatment to reverse the vasoconstriction; losartan should be discontinued permanently
E) This is losartan toxicity from drug accumulation — at eGFR 34 mL/min/1.73m2, losartan's active metabolite EXP-3174 accumulates to toxic levels; this manifests as AKI from direct tubular toxicity; losartan must be permanently replaced with a non-RAAS antihypertensive
ANSWER: B
Rationale:
This presentation is the clinical manifestation of the triple whammy AKI that sick day guidance is specifically designed to prevent. The viral gastroenteritis with 4 days of vomiting and poor oral intake created significant volume depletion — reducing renal perfusion pressure and triggering homeostatic RAAS activation to maintain intraglomerular pressure. In a patient on RAAS inhibition (losartan), the compensatory efferent arteriolar constriction that normally maintains GFR pressure when systemic BP is low is specifically blocked. The combination of: (1) reduced intravascular volume from illness; (2) peripheral vasodilation from amlodipine without the normal vasoconstrictive compensatory response; and (3) blocked efferent arteriolar autoregulation from losartan — reduces intraglomerular pressure to the point of causing AKI. The creatinine rise from 1.6 to 2.8 mg/dL (a 75% increase) and low BP of 108/62 mmHg are consistent with hemodynamic AKI from volume depletion and impaired autoregulation. Management focuses on restoring volume (IV normal saline) while temporarily withholding both the RAAS inhibitor and the CCB. Once the patient is volume-replete, hemodynamically stable, and creatinine is trending downward, the RAAS inhibitor should be gradually reintroduced — because its long-term renoprotective benefit (confirmed by the baseline UACR of 340 mg/g on losartan) outweighs the risk of a reversible acute hemodynamic AKI. This is an important clinical teaching point: AKI from triple whammy in the context of an intercurrent illness does not mean the RAAS inhibitor should be permanently discontinued — it means sick day guidance should be reinforced for future illnesses.
Option A: Option A is incorrect because the acute creatinine rise in the context of volume depletion and illness is AKI, not irreversible CKD progression; and the low BP reflects volume depletion, not cardiac failure.
Option C: Option C is incorrect because no contrast exposure is described; the AKI has a clear mechanism from volume depletion and drug interactions.
Option D: Option D is incorrect because potassium of 5.1 mEq/L does not cause renal vasoconstriction; this mechanism does not exist.
Option E: Option E is incorrect because losartan and its metabolite EXP-3174 are primarily hepatically eliminated and do not accumulate significantly through direct tubular toxicity in CKD.
BEFORE YOU MOVE ON
The pharmacology of hypertension in CKD is pharmacology in its most consequential form — where the drugs you choose, the doses you target, the transitions you make as GFR declines, and the monitoring you provide determine whether a patient reaches ESRD or maintains kidney function for decades. Before moving to higher tiers, confirm you can explain: why RAAS inhibitors are more renoprotective than equivalent BP reduction from a CCB; why a 30% creatinine rise after starting an ACEi is evidence of success, not harm; why the diuretic class must change at eGFR 30; why dual RAAS blockade is specifically contraindicated; and why SGLT2 inhibitors protect the glomerulus through a mechanism that is anatomically opposite to RAAS inhibition. If you can explain each of these at the pharmacological level, you are ready for Tier 1.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.